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Recombining the structures of HIV integrase, RuvC and RNase H
The recently reported crystal structures of two recombination enzymes,
the catalytic domain of HIV integrase and Escherichia coli RuvC, an
endonuclease, are surprisingly similar to that of ribonuclease H suggesting
the possibility that they have a common enzymatic mechanism.
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Thirty years after the proposal of the Holliday junction as
an intermediate in homologous recombination of DNA,
the crystal structures of Escherichia coli RuvC [1], an
endonuclease that specifically cleaves Holliday junctions,
and HIV integrase [2], (which integrates HIV DNA into
the chromosome) have been determined. The AIDS epi-
demic has greatly stimulated HIV-related research, and
HIV integrase has become one of the best studied inte-
gration enzymes since its discovery 10 years ago. In paral-
lel, RuvC has also become one of the best characterized
enzymes involved in homologous recombination. The
crystal structures of these two recombination enzymes
show that their folding topology and active-site geometry
are similar to those of the ribonuclease H (RNase H)
enzymes from HIV [3] and E. coli [4,5] despite the lack of
detectable amino acid sequence homology. HIV integrase
and RuvC may therefore employ the general two-metal-
ion trans-esterification mechanism proposed for RNase H
[3,5,6], the 3' to 5' exonuclease of Klenow fragment [7],
polymerases [8] and ribozymes [9]. The crystal structure
of HIV integrase provides the basis for rational drug
design against HIV integrase which, unlike the viral pro-
tease or reverse transcriptase presently used in drug
design, has no host homolog.
Retroviral integration and integrase
An essential process in the retroviral lifecycle is the inte-
gration of the viral double-stranded DNA into host
chromosomes [10,11]. This integration process is com-
pleted in three discrete steps: firstly, the 3' ends of the
viral DNA are processed to expose the absolutely con-
served dinucleotides CA-oH3Y; secondly, strand-transfer
of the processed viral DNA into the target DNA takes
place, during which the staggered cleavage of target
DNA and ligation of the viral 3' and target 5' ends are
concerted; and finally, the viral 5' ends are processed and
the gaps between the viral 5' and target 3' ends are
repaired. The retroviral-encoded integrase is able to cat-
alyze the first two steps of integration in vitro in the pres-
ence of the divalent cations, Mg2 + or Mn 2+ , and
accomplishes both the hydrolysis and strand-transfer of
DNA in a trans-esterification reaction using first OH-
and then the 3'-OH of DNA as nucleophiles. The
reverse of the second step, called the disintegration reac-
tion, cleaves off an invading viral DNA branch and
reseals the target DNA [12] and is used as an assay of
integrase activity. The third step of integration is believed
to be carried out by host DNA-repair enzymes.
HIV integrase contains 288 amino acids and can be
divided into three functional domains [13]. The N-termi-
nal domain (residues 1-49) contains a zinc-binding motif
with two histidine and two cysteine residues as putative
Zn2 + ligands, which is conserved among all retroviral and
retrotransposon integrases. The central core domain (resi-
dues 50-212) contains three acidic residues that are invari-
ant among integrases and are arranged in the same con-
served sequence pattern as that of the catalytic residues in
bacterial transposases [14]. Mutation of any one of the
three acidic residues renders an integrase inactive. In con-
trast, the remaining C-terminal residues of the integrase
family have quite diverse sequences. The central core
domain alone is capable of catalyzing the disintegration
reaction but not the 3' processing and strand-transferring
reactions [13], whereas the N- and C-terminal domains
are required for the viral integration and are thought to be
critical for substrate specificity. Integrase forms dimers,
and multimers of dimers, in solution: these are probably
the functional units, because it has been shown that in-
active integrase molecules that are defective in different
domains can complement one another [15,16].
The determination of the crystal structure of HIV inte-
grase core domain [2] is a triumph of the combination of
mutagenesis and multiwavelength anomalous diffraction
(MAD) techniques [3]. The major barrier to obtaining
the crystal structure of this enzyme, which has prevented
many laboratories from pursuing it, has been the insolu-
bility of both intact integrase and the catalytic core
domain. The problem was overcome by systematically
mutating each of the hydrophobic residues in every
hydrophobic patch to a lysine, (this was achieved by
Craigie and Jenkins, two of the authors of [2]). The sub-
stitution of Phel86 by lysine resulted in a much more sol-
uble, monodispersed integrase core domain that readily
formed diffraction-quality crystals. Davies' group then
solved the catalytic core domain structure in two months
using the MAD technique on the selenomethionine-
derivatized protein [2].
RuvC and the Holliday junction
The Holliday junction is a four-way cruciform-like
structure formed during homologous recombination
between two DNA duplexes by RecA-catalyzed homol-
ogous pairing of these duplexes and strand exchange
[17,18]. E. coli RuvC is a 172 amino acid endonuclease
that binds specifically to the Holliday junction and
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Fig. 1. (opposite). Stereo ribbon diagrams (left), and topological diagrams (right), of (a) E. coil HIV RNase H, (b) HIV RNase H domain,
(c) the core domain of HIV integrase and (d) E. coli RuvC [36]. Secondary structures are defined using program DSSP [37] and the four
structures are superimposed based on the least-squares fitting of the two structurally conserved carboxylates and the first four strands in the
{-sheet [38]. The topologically conserved 13-sheet and helices are shown in dark gray, the disordered loops in HIV RNase H and HIV inte-
grase are represented by the dashed lines; the three conserved carboxylates required for the enzymatic activity are drawn in ball-and-stick
representation. In HIV integrase (c), the third carboxylate is located in the disordered loop, and therefore is not shown. The fourth carboxy-
lates in RuvC and RNases H are shown lighter. The two Mn2+ ions bound in the active site of HIV RNase H (b) are also shown as light gray
spheres. In the topological diagrams of the four enzymes, 3-strands are shown as thick arrows, a-helices as rectangular boxes and loops as
thin lines. The location of the active-site carboxyl triads are marked by asterisks and the fourth carboxylates marked by plus signs.
resolves it into two separated DNA duplexes [19,20].
The binding of RuvC to Holliday junctions or struc-
turally equivalent cruciform DNAs does not require
divalent cations, but RuvC is catalytically active only
when the two duplex DNAs are homologous and Mg2+
is present [19,20]. The binding of RuvC to the Holliday
junction changes its conformation and makes it hyper-
sensitive to hydroxyl-radical cleavage, particularly around
the base pairs adjacent to the crossover point [21]. The
cleavage of the four-way DNA junction by RuvC then
occurs symmetrically on two strands of the same polarity
and preferentially at the 3' side of a thymidine [19-22].
RNase H from HIV and E. coli
RNase H specifically hydrolyzes RNA strands in RNA-
DNA hybrids in the presence of either Mg2 + or Mn2+;
its reaction mechanism differs from most ribonucleases
but resembles deoxyribonucleases and many ribozymes,
as it does not use the 2'-OH of ribose as a nucleophile to
form a 2' to 3' cyclic phosphate intermediate that leads
to a 3' phosphate but rather it produces 3'-OH and 5'
phosphate groups [23,24]. The E. coli RNase H com-
prises a single polypeptide chain of 155 amino acid
residues [24], whereas the HIV RNase H is a 130 amino
acid domain of the viral reverse transcriptase and is indis-
pensable for the replication of genomic RNA to double-
stranded DNA [25]. Crystal structures of both RNases H
were determined several years ago [3-5] and shown to be
homologous with a high degree of structural similarity
despite their relatively low sequence identity [3].
Comparison of HIV integrase, RuvC and RNase H structures
The crystal structures of HIV integrase and RuvC are
very similar to those of E. coli and HIV RNase H [1,2].
All four structures share a similar oat-fold containing a
central five-stranded mixed 1-sheet surrounded by
ao-helices on both sides, which are in the same topological
order (Fig. 1): three antiparallel A-strands followed by two
(x-turn-1 units that position the two parallel helices on
one side of the 3-sheet and finish with a third helix on
the opposite side of the sheet. However, the lengths of the
secondary-structure elements, the twist of the -sheet
and the relative positions of helices, vary among the four
structures (Fig. la). The RNase H structures also have
additional helices and loops inserted between the two
ot-turn-3 units, which form part of the substrate-binding
surface inferred from structural studies. Integrase and
RuvC, in contrast, have two additional helices on the
other side of the 1-sheet next to the C-terminal helix.
In RuvC, these three C-terminal helices together with
the 13-sheet form a deep cleft that Morikawa and his
colleagues suggest is suitable for DNA binding [1]. Finally,
although HIV integrase and RuvC form functional
dimers in solution [15,16,19,20], in the crystal structures
they dimerize using completely different interfaces [1,2].
These four enzymes have the same folding topology
as observed for several other proteins, such as the nucleo-
tide-binding domains of a yeast hexokinase [26], the heat
shock protein, hsp70, [27] actin [28] and the connection
domain of HIV reverse transcriptase [29,30].
Despite the lack of close resemblance, these four enzymes
have remarkably similar active sites that consist of a set of
three highly conserved carboxylates that are absolutely
required for catalytic activity. In all four structures, two
of the three carboxylates are located in identical positions
relative to the tertiary structure, one in the first 3-strand
and the other next to the C terminus of the fourth
3-strand (Fig. 1). The location of the third carboxylate
varies: in RuvC it is on the fifth helix, while in the inte-
grase it occurs on a disordered loop leading into the third
helix, which is actually in a vicinity similar to that in
RuvC; in RNase H, however, the third carboxylate is on
the first helix. If the four structures are aligned by super-
position of their P-sheets and the first two carboxylates,
the third carboxylate in RNase H is on the opposite side
of the 3-sheet from those in HIV integrase and RuvC.
However, disregarding the alignment of the protein ter-
tiary structures, Morikawa and his coworkers have
reported that all atoms of the carboxyl triad from RuvC
can be superimposed onto those of E. coli RNase H with
a root mean square deviation of 2.1 A [1]. RuvC and
RNase H also have a fourth conserved carboxylate that is
required for catalysis in RuvC [1]. It can be replaced by a
carboxyl amide or imidazole, which could serve as a
metal ligand, (though less optimally than the carboxylate)
in E. coli RNase H [31].
The topological resemblance among the structures of
HIV integrase, RuvC and RNase H, particularly their
analogous catalytic carboxylates, their shared requirement
for divalent cations, and the similar trans-esterification
function, raises the possibility that they employ a com-
mon 'carboxylate-metal ion' catalytic mechanism, similar
to that proposed for RNase H, although neither of the
two new crystal structures have been studied in the pres-
ence of divalent cations [1,2]. A 'carboxylate-chelated
two-metal-ion' catalytic mechanism, originally proposed
for the 3' to 5' exonuclease of Klenow fragment [7,32]
and later extended to the polymerases [8], ribozymes
[7,9] and RNase H [3,5], would be feasible for the
hydrolysis as well as the polynucleotidyl transfer on both
RNAs and DNAs. Two divalent metal ions, spaced
3.8-4.0 A apart, have been observed in the active site of
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the isolated HIV RNase H domain [3] and in the intact
HIV reverse transcriptase (TA Steitz et al., unpublished
data). Although only one Mg2+ ion has been detected
thus far in E. coli RNase H [33], the second metal ion
might be missing because of its weak binding in the
absence of substrates. The two metal ions chelated by
carboxylates, as shown in the 3' to 5' exonuclease [7],
would play a role in activating hydroxyl nucleophiles and
stabilizing the penta-covalent phosphate intermediates of
the nucleotidyl transfer reactions.
In summary, RNase H, RuvC and HIV integrase repre-
sent a structural and catalytic motif for a class of nucleases
and polynucleotidyl transferases that use a general folding
scheme and a similar catalytic center to accomplish a
trans-esterification reaction on diverse substrates by what
may turn out to be a common enzymatic mechanism. An
additional example is provided by the crystal structure of
the catalytic domain of phage Mu transposase, a member
of a large integration enzyme family, which also contains
an RNase H-like fold and a conserved catalytic triad
(P Rice and K Mizuuchi, personal communication).
Prospects for anti-HIV drug design
Anti-HIV drug design has thus far targeted the viral pro-
tease and reverse transcriptase because of the advanced
knowledge of their three-dimensional structures. Progress
in designing highly potent drugs specifically against the
viral protease is promising [34,35]. Until now, screening
for inhibitors of HIV integrase has been carried out
without the benefit of structural knowledge. In the light
of the new atomic structure of the catalytic domain of
HIV integrase and the suggestion of a possible catalytic
mechanism, drugs specifically targeting the HIV inte-
grase active site can be contemplated. The challenge with
this enzyme, as with the other two HIV enzymes, will
be to find an inhibitor that is not rendered inactive by
mutation of the enzyme.
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